Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer

25 Jun 2018

Abstract excerpt

Abstract Purpose: Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer (SCLC), a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patient-relevant models to interrogate novel therapies. Following our development of circulating tumor cell patient–derived explants (CDX) as models that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29941481
DOI: 10.1158/1078-0432.ccr-17-2805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung CancerPMID 29941481Read ↗

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve ResponsesSemantic proximity Read ↗

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity Read ↗

Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explantsSemantic proximity Read ↗

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity Read ↗

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung CancerSemantic proximity Read ↗

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerSemantic proximity Read ↗

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancerSemantic proximity Read ↗

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsSemantic proximity Read ↗

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patientsSemantic proximity Read ↗

An optimized method to culture human primary lung tumor cell spheroidsSemantic proximity Read ↗

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.Semantic proximity Read ↗

Induced Degradation of Lineage-specific Oncoproteins Drives the Selective PARP1 Inhibitor Toxicity in Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.